Multi-Specific Monoclonal Antibodies

February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Spotlight

T2 Biosystems

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need.

OTHER WHITEPAPERS

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

More Whitepapers

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Spotlight

T2 Biosystems

OTHER WHITEPAPERS

Validation of ICON™ Automated Cell Counting and Viability Assay

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

Considerations for migrating a drug product presentation from vial to pre-filled syringe

Biosimilars – commercial best practices in the age of sustainability

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

Validation of ICON™ Automated Cell Counting and Viability Assay

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

Considerations for migrating a drug product presentation from vial to pre-filled syringe

Biosimilars – commercial best practices in the age of sustainability

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

Spotlight

T2 Biosystems

Events